- Home
- CVI vs PRAX Comparison
CVI vs PRAX Comparison
Compare CVI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVI
- PRAX
- Stock Information
- Founded
- CVI 1906
- PRAX 2015
- Country
- CVI United States
- PRAX United States
- Employees
- CVI N/A
- PRAX N/A
- Industry
- CVI Integrated oil Companies
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- CVI Energy
- PRAX Health Care
- Exchange
- CVI Nasdaq
- PRAX Nasdaq
- Market Cap
- CVI 3.6B
- PRAX 4.0B
- IPO Year
- CVI 2007
- PRAX 2020
- Fundamental
- Price
- CVI $36.92
- PRAX $190.41
- Analyst Decision
- CVI Strong Sell
- PRAX Strong Buy
- Analyst Count
- CVI 3
- PRAX 12
- Target Price
- CVI $26.67
- PRAX $212.42
- AVG Volume (30 Days)
- CVI 1.2M
- PRAX 815.0K
- Earning Date
- CVI 10-29-2025
- PRAX 11-05-2025
- Dividend Yield
- CVI N/A
- PRAX N/A
- EPS Growth
- CVI 140.58
- PRAX N/A
- EPS
- CVI 1.65
- PRAX N/A
- Revenue
- CVI $7,299,000,000.00
- PRAX $7,463,000.00
- Revenue This Year
- CVI N/A
- PRAX N/A
- Revenue Next Year
- CVI $1.72
- PRAX $44.43
- P/E Ratio
- CVI $22.47
- PRAX N/A
- Revenue Growth
- CVI N/A
- PRAX 364.98
- 52 Week Low
- CVI $15.10
- PRAX $26.70
- 52 Week High
- CVI $41.67
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- CVI 53.56
- PRAX 65.01
- Support Level
- CVI $35.44
- PRAX $159.74
- Resistance Level
- CVI $37.52
- PRAX $188.53
- Average True Range (ATR)
- CVI 1.79
- PRAX 14.09
- MACD
- CVI -0.19
- PRAX -4.40
- Stochastic Oscillator
- CVI 36.08
- PRAX 66.19
About CVI CVR Energy Inc.
CVR Energy Inc is a holding company that engages in petroleum refining and nitrogen fertilizer manufacturing through its subsidiaries. Subsidiaries include several complex, full-coking crude oil refineries, along with a crude oil gathering system, pipelines and storage tanks, and marketing and supply. The company's refineries can process blends of a variety of crude oil ranging from heavy sour to light sweet crude oil. Crude oil for CVR's refineries is supplied through its wholly-owned gathering system and pipeline. From its refineries, CVR supplies products through tanker trucks directly to customers located in close geographic proximity and customers at throughput terminals. The company's customers include retailers, railroads, and farm cooperatives.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.